Terns Pharmaceuticals, Inc. Change in other assets and liabilities

Change in other assets and liabilities of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Change in other assets and liabilities growth rates and interactive chart.


Highlights and Quick Summary

  • Change in other assets and liabilities for the quarter ending March 31, 2022 was $-2.04 Million (a -359.47% decrease compared to previous quarter)
  • Year-over-year quarterly Change in other assets and liabilities decreased by -399.85%
  • Annual Change in other assets and liabilities for 2021 was $434 Thousand (a -79.52% decrease from previous year)
  • Annual Change in other assets and liabilities for 2020 was $2.12 Million (a -362.9% decrease from previous year)
  • Annual Change in other assets and liabilities for 2019 was $-806 Thousand (a -53.06% decrease from previous year)
  • Twelve month Change in other assets and liabilities ending March 31, 2022 was $-376 Thousand (a -186.64% decrease compared to previous quarter)
  • Twelve month trailing Change in other assets and liabilities decreased by -228.77% year-over-year
Trailing Change in other assets and liabilities for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-376 Thousand $434 Thousand $130 Thousand $292 Thousand
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Change in other assets and liabilities of Terns Pharmaceuticals, Inc.

Most recent Change in other assets and liabilitiesof TERN including historical data for past 10 years.

Interactive Chart of Change in other assets and liabilities of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Change in other assets and liabilities for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-2.04
2021 $0.79 $0.2 $0.68 $-1.23 $0.43
2020 $0.48 $0.36 $0.21 $0.38 $2.12
2019 $-0.81
2018 $-1.72

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.